Premium
Treatment of bronchial asthma with terfenadine; a randomized controlled trial.
Author(s) -
Taytard A,
Beaumont D,
Pujet JC,
Sapene M,
Lewis PJ
Publication year - 1987
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1987.tb03240.x
Subject(s) - terfenadine , bronchoconstriction , placebo , medicine , asthma , histamine h1 receptor , antagonist , histamine , anesthesia , antihistamine , inhalation , randomized controlled trial , receptor , alternative medicine , pathology
1. Terfenadine, a histamine H1‐receptor antagonist, was studied in 52 patients with stable mild perennial asthma with an allergic basis. 2. After a placebo run‐in period, patients were randomly allocated to either terfenadine 120 mg twice daily or placebo. After 2 weeks they were crossed over to the other treatment. Forty‐six patients completed the study. 3. Terfenadine was significantly more effective than placebo as measured by peak expiratory flows and by symptom scores. 4. These results suggest that histamine may play a more significant role in asthmatic bronchoconstriction than is currently recognised.